Office-use compounding in Oklahoma

What the rule requires in practice

Each item carries a confidence level. Verbatim rule text is high confidence; a reading of how two provisions interact, or a source that could not be re-verified, is not.

What died, and in which order — the order is the interesting partHigh confidence

The sterile office-use rule was revoked effective 27 August 2015. The rule titled for compounding for a prescriber’s office use was revoked effective 11 September 2017. Sterile went first, by two years, which is the reverse of what anyone would guess and is worth stating because it forecloses the argument that Oklahoma merely tidied one rule into another. Nothing replaced either. That is a vacuum measured in years, not months.Both dates or neither. A page citing one revocation has half the fact, and a page citing either rule as current law is citing something that has not existed for most of a decade.

The trap in the codified volumeHigh confidence

Oklahoma keeps the revoked rules’ titles in the published Title 535 and prints the revocation marker on the following line. A reader skimming headings, or a scraper capturing them, sees a rule named for office-use compounding and reproduces it perfectly — with the one line that kills it left behind.

What survives is a supply permit, not a compounding permissionHigh confidence

The drug supplier permit costs $20 and lets a pharmacy supply prescribers for their office administration. Two conditions sit on it: the holder must have a valid retail pharmacy licence, and its drug-supplier sales may not exceed five per cent of the pharmacy’s total annual sales.

Whether that lane reaches compounded product is the open questionLow confidence

The definition speaks of legend drugs. A separate rule, 535:15-7-3(a), mentions a compounded preparation — but inside a restriction, which cuts both ways: it can be read as contemplating compounded product in the lane, or as fencing it out. Nothing in the text settles it and no board ruling construing it was located.This single question decides whether Oklahoma is narrow or effectively unruled for compounded preparations, which is why the confidence flag here is low and stays low. A Board declaratory ruling would settle it in one document. Until then a practice should not build on either reading.

The 5% clause here is a ceiling on a permit, not an exemption from oneHigh confidence

This is unique among the states reviewed here and it inverts the usual advice. Elsewhere a five-per-cent clause is a safe harbour a seller falls into. In Oklahoma it is a condition on a permit the pharmacy affirmatively holds, so breaching it violates the permit rather than merely losing an exemption. And it caps the seller’s entire office-supply book across every prescriber it serves, measured in the pharmacy’s own revenue — not the buying practice’s.Any pitch that presents the five per cent as headroom for one clinic has the denominator wrong and the direction wrong. The number belongs to the supplier and is shared across all of its customers.

Quantity and labellingHigh confidence

Two limits exist and only one is numeric: the five-per-cent ceiling above, and a qualitative bar on distributing an "inordinate amount" at 535:15-10-2. There is no human label legend — "office use only", "not for resale" and "non-patient specific" all return zero. The only office-use legend Oklahoma mandates is veterinary.

Entity or person — split by drug class, and the mirror of ConnecticutHigh confidence

For controlled substances the authority attaches to the entity, and per SUITE: the registration rule requires a separate registration for each suite a registrant occupies, and the statute demands beneficial-owner disclosure from every legal-entity applicant. For everything else it attaches to the person, and no entity credential exists to obtain — 59 O.S. § 355.1(A) runs to a licensed practitioner and that is the whole of it.A two-suite practice therefore needs two controlled-substance registrations at one street address, and a mixed order of controlled and non-controlled office stock can need two different names on two different purchase orders in the same state.

Last change, and one dated aheadHigh confidence

The revocations are the last events on the office-use side. Separately, a 2026 act rewrites the statutory definition of "prescription" effective 1 November 2026 to include independently authorised advanced practice nurses and physician assistants practising without a delegating physician. Every lawful Oklahoma shipment runs through that word, so it changes who can originate one.The Board also has a set of 2026 chapter 15 rules whose status its own materials describe inconsistently — one page still labels them proposed while the Board’s current law book already prints the amended text. No effective date for those is published here.

Oklahoma at a glance

Receiving 503B office stock in Oklahoma

Oklahoma is one of the states where searching for the literal term works — it licenses outsourcing facilities under that name. The surprise is on the controlled-substance side, where the registration comes from neither the pharmacy board nor the medical board.

Everything above this heading answers the supply question: may a state-licensed 503A pharmacy ship non-patient-specific stock? This section answers the other half. Registration with FDA under section 503B is a federal exemption from federal law and preempts no state licensing scheme, so it is never the whole answer on its own — a state credential is the norm rather than the exception, it is not always issued by the board of pharmacy, and in some states the category you would search for does not exist. What Oklahoma asks for is set out below, including where we could not establish it.

What the 503B must hold to ship inHigh confidence

An outsourcing facility licence from the Board of Pharmacy, $200 a year, required per facility and per location. Rule 535:20-6-3(h) adds that a facility also filling patient-specific prescriptions needs an Oklahoma pharmacy or non-resident pharmacy licence in addition.

Does your practice need a permit?High confidence

No, and none exists to obtain. The Board publishes nineteen fee categories and not one is a for-profit clinical facility. The only clinic-shaped credential is a charitable clinic pharmacy licence at $75, confined to non-profit operation, free-of-charge supply and individual prescriptions — none of which describes a commercial practice holding office stock.

Administer vs dispenseMedium confidence

Dispensing is what pulls an Oklahoma prescriber into a registration duty, and the duty runs to that prescriber’s own professional board rather than to pharmacy. Possession and administration in the course of practice sit under the general rule that only a licensed practitioner may dispense dangerous drugs to that practitioner’s patients.

Scheduled (controlled) stockHigh confidence

Yes, and from a body that is neither health board: the Oklahoma Bureau of Narcotics and Dangerous Drugs Control, a standalone law-enforcement bureau whose inspectors are peace officers. Registration runs per principal place of business and separately per suite, and expires 31 October.This is a distinct shape from Alabama, the other state in this file whose controlled-substance registrar is not the pharmacy board — Alabama routes to a health board, Oklahoma routes outside health regulation altogether. A compliance matrix sending an Oklahoma physician to either the pharmacy board or the medical board is wrong. The fee was not verified and is not published here.

How to check a facility’s credential before you order is set out in how to place an office-use order.

What this page does not establish

• Whether the surviving drug-supplier permit reaches compounded preparations is unresolved on the text, and it is the highest-value open question on this page. It decides Oklahoma’s verdict for this vertical, and a Board declaratory ruling would settle it.
• The state’s own link to the codified title has rotted — the Board’s laws page points at a host that no longer resolves. The copy relied on here is the Secretary of State’s publication storage. Note that the two available sources disagree on currency: the codified PDF runs through an August 2024 register while the Board’s own law book is current to July 2026.
• An attorney-general opinion is flagged in the citator as construing 59 O.S. § 355.1 at length, and it is unread. That section carries the entity-versus-person answer for non-controlled drugs, so the opinion is directly load-bearing.
• We could not retrieve a peptide-adjacent statute on human growth hormone: the state’s case site imposed a challenge. It could carry a substance-specific condition invisible in the pharmacy rules.
• We searched no case law or disciplinary orders for this state, and search engines were unavailable when it was researched. Read nothing into that silence — it means we have not looked, not that nothing is there.